报告摘要事件:2025年3月30日,康方生物公布2024年全年业绩,公司全年实现收入21.24亿元,同比下降53.08%(主要原因是2023年从SUMMIT收到大额首付款)。其中,商业销售扣除分销成本后的收入为20.02亿元,同比增长24.88%,主要得益于两款核心双抗产品卡度尼利(PD-1/CTLA-4)和依沃西(PD-1/VEGF)的销售快速增长。两款双抗新药纳入医保目录,多适应症获批销售放量...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.